Login to Your Account

End of the Road at Last?

La Jolla: No Cash, No Options After Failed Preclinical Study

By Jennifer Boggs

Tuesday, May 24, 2011
In an industry riddled with disappointing data, regulatory setbacks and a depressing 90 percent-plus failure rate, biotech companies have learned to be resilient, raising money whenever possible – and sometimes when it almost isn't – and often reinventing themselves in the wake of disastrous pipeline flops.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription